Dr. Nazik Hammad presents Keynote-177 (GI cancer)

KEYNOTE-177: translating results for patients and clinicians KEYNOTE-177 KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy Dr. Chu on the Impact of the KEYNOTE-177 Trial in mCRC ASCO 2020 | Keynote-177: Pembrolizumab versus Quimioterapia para cólon MSI-H Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal c... Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRC Thierry Andre, ASCO20: Phase III KEYNOTE-177 Trial of Pembrolizumab in Metastatic Colorectal Cancer Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC